Appointment of Vice President Corporate Development
27-Apr-10 Medivir has appointed Håkan Wallin as Vice President of Corporate Development effective from 1 May 2010. The new established position as Vice President of Corporate Development is a further step to strengthen Medivir’s organisation to support the Company’s ongoing goal to achieving profitability within a five years time horizon. Håkan has been instrumental in leading Medivir’s recent process to develop a new portfolio management system which was concluded in the first quarter of 2010 with a review of all R&D projects resulting in a more focused R&D portfolio. In this process Håkan acted independently through his own consultancy company.
Håkan has significant experience from the life science industry both from the finance and management industry. Håkan has carried out consultancy and advisory engagements for Nordic and International life science companies in various positions for more than 10 years. Most recently, Håkan has acted through his own consultancy company, HWA Advisory & Capital AB. During 2000 to 2006, Håkan was partner at ABG Sundal Collier’s corporate finance team where he was responsible for the firm’s life science franchise. Håkan previous positions also include CEO of Libertas Capital Nordic AB, member of Ernst & Young Corporate Finance team in Stockholm as well as being an accountant at Arthur Andersen both in Stockholm and Atlanta, USA.
“I am pleased to have Håkan Wallin on board as Vice President Corporate Development as he will add additional competence to our management team. His broad experience from the life science sector will further enhance our strategic focus to be a profitable, medium-sized in high growth with its prime strength in infectious diseases within a five-year period” says Ron Long, CEO and President.
For additional information, please contact
Rein Piir, CFO & VP Investor Relations, +46 (0)8 5468 3123 or +46 708 537 292.
For more information on Medivir, please see the company website: www.medivir.se